1. Kyritsis, AP, Boussios, S, Pavlidis, N. Cancer specific risk in multiple sclerosis patients. Crit Rev Oncol Hematol 2016; 98: 29–34.
Google Scholar | Crossref | Medline2. Fois, AF, Wotton, CJ, Yeates, D, et al. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: Record linkage studies. J Neurol Neurosurg Psychiatry 2010; 81: 215–221.
Google Scholar | Crossref | Medline | ISI3. Gaindh, D, Kavak, KS, Teter, B, et al. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. J Neurol Sci 2016; 370: 13–17.
Google Scholar | Crossref | Medline4. Goldacre, MJ, Seagroatt, V, Yeates, D, et al. Skin cancer in people with multiple sclerosis: a Record linkage study. J Epidemiol Community Health 2004; 58: 142–144.
Google Scholar | Crossref | Medline | ISI5. Midgard, R, Glattre, E, Gronning, M, et al. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta Neurol Scand 1996; 93: 411–415.
Google Scholar | Crossref | Medline | ISI6. Moller, H, Kneller, RW, Boice, JD, et al. Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta Neurol Scand 1991; 84: 214–220.
Google Scholar | Crossref | Medline | ISI7. Nielsen, NM, Rostgaard, K, Rasmussen, S, et al. Cancer risk among patients with multiple sclerosis: A population-based register study. Int J Cancer 2006; 118: 979–984.
Google Scholar | Crossref | Medline | ISI8. Nørgaard, M, Veres, K, Didden, EM, et al. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study. Mult Scler Relat Disord 2019; 28: 81–85.
Google Scholar | Crossref | Medline9. Ragonese, P, Aridon, P, Vazzoler, G, et al. Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: A cohort study. BMC Neurol 2017; 17: 155.
Google Scholar | Crossref | Medline10. Sumelahti, ML, Pukkala, E, Hakama, M. Cancer incidence in multiple sclerosis: A 35-year follow-up. Neuroepidemiology 2004; 23: 224–227.
Google Scholar | Crossref | Medline | ISI11. Sun, LM, Lin, CL, Chung, CJ, et al. Increased breast cancer risk for patients with multiple sclerosis: A nationwide population-based cohort study. Eur J Neurol 2014; 21: 238–244.
Google Scholar | Crossref | Medline12. Wynn, DR, Rodriguez, M, O’Fallon, WM, et al. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990; 40: 780–786.
Google Scholar | Crossref | Medline | ISI13. Marrie, RA, Reider, N, Cohen, J, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler 2015; 21: 294–304.
Google Scholar | SAGE Journals | ISI14. Ghajarzadeh, M, Mohammadi, A, Sahraian, MA. Risk of cancer in multiple sclerosis (MS): A systematic review and meta-analysis. Autoimmunity Rev 2020; 19: 102650.
Google Scholar | Crossref | Medline15. Lebrun, C, Rocher, F. Cancer risk in patients with multiple sclerosis: Potential impact of disease-modifying drugs. CNS Drugs 2018; 32: 939–949.
Google Scholar | Crossref | Medline16. Dolati, S, Babaloo, Z, Jadidi-Niaragh, F, et al. Multiple sclerosis: Therapeutic applications of advancing drug delivery systems. Biomed Pharmacother 2017; 86: 343–353.
Google Scholar | Crossref | Medline17. Pardo, G, Jones, DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: Safety and immunologic considerations. J Neurol 2017; 264: 2351–2374.
Google Scholar | Crossref | Medline18. Lebrun, C, Debouverie, M, Vermersch, P, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 2008; 14: 399–405.
Google Scholar | SAGE Journals | ISI19. Schmidt, M, Pedersen, L, Sørensen, HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29: 541–549.
Google Scholar | Crossref | Medline | ISI20. Koch-Henriksen, N, Magyari, M, Laursen, B. Registers of multiple sclerosis in Denmark. Acta Neurol Scand 2015; 132: 4–10.
Google Scholar | Crossref | Medline21. Gjerstorff, ML . The Danish Cancer Registry. Scand J Public Health 2011; 39: 42–45.
Google Scholar | SAGE Journals | ISI22. Pukkala, E, Engholm, G, Højsgaard Schmidt, LK, et al. Nordic Cancer Registries – an overview of their procedures and data comparability. Acta Oncologica (Stockholm, Sweden) 2018; 57: 440–455.
Google Scholar | Crossref | Medline23. Lund, EM, Clemmensen, IH, Storm, HH. Survey of Nordic Cancer Registries. 2000. Available at: https://www.ancr.nu/dyn/resources/File/file/7/4247/1412940269/total_document_survey_optimeret.pdf (accessed October 2021)
Google Scholar24. Lynge, E, Sandegaard, JL, Rebolj, M. The Danish National Patient Register. Scand J Public Health 2011; 39: 30–33.
Google Scholar | SAGE Journals | ISI25. Schmidt, M, Schmidt, SA, Sandegaard, JL, et al. The Danish National Patient Registry: A review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449–490.
Google Scholar | Crossref | Medline | ISI26. Gco.iarc.fr. Cancer today, http://gco.iarc.fr/today/data-sources-methods (2019).
Google Scholar27. Pottegård, A, Friis, S, Stürmer, T, et al. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin Pharmacol Toxicol 2018; 122: 451–459.
Google Scholar | Crossref | Medline28. Grytten, N, Myhr, KM, Celius, EG, et al. Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. Mult Scler 2020; 26: 1569–1580.
Google Scholar | SAGE Journals | ISI29. Bahmanyar, S, Montgomery, SM, Hillert, J, et al. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009; 72: 1170–1177.
Google Scholar | Crossref | Medline | ISI30. Achiron, A, Barak, Y, Gail, M, et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 2005; 89: 265–270.
Google Scholar | Crossref | Medline | ISI31. Kingwell, E, Bajdik, C, Phillips, N, et al. Cancer risk in multiple sclerosis: Findings from British Columbia, Canada. Brain 2012; 135: 2973–2979.
Google Scholar | Crossref | Medline32. Bloomgren, G, Richman, S, Hotermans, C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.
Google Scholar | Crossref | Medline | ISI33. Lebrun, C, Vermersch, P, Brassat, D, et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol 2011; 258: 1304–1311.
Google Scholar | Crossref | Medline34. Kingwell, E, Evans, C, Zhu, F, et al. Assessment of cancer risk with beta-interferon treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 1096–1102.
Google Scholar | Crossref | Medline35. Dafni, U . Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011; 4: 363–371.
Google Scholar | Crossref | Medline36. Agarwal, P, Moshier, E, Ru, M, et al. Immortal time bias in observational studies of time-to-event outcomes: Assessing effects of postmastectomy radiation therapy using the National Cancer Database. Cancer Control: Journal of the Moffitt Cancer Center 2018; 25: 1073274818789355.
Google Scholar | SAGE Journals | ISI